Non-specific immunosuppressants in the treatment of multiple sclerosis

Clinical Neurology and Neurosurgery

Volumn 106, Issue 3, 2004, Pages 263-269

  Confavreux, Christian ^a   Vukusic, Sandra ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Degeneration; Immunosuppressants; Inflammation; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; MEPREDNISONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; STEROID;

ANEMIA; BRAIN ATROPHY; CARCINOGENESIS; CLINICAL TRIAL; DISABILITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTOPENIA; META ANALYSIS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; QUADRIPLEGIA; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS;

EID: 2642552117     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2004.02.012     Document Type: Article

References (39)

1. Edan G., Miller D., Clanet M., Confavreux C., Lyon-Caen O., Lubetzki C., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multi-center study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry. 6:1997;72-78
2. Hartung H-P., Gonsette R., Konig N., Kwiecinski H., Guseo A., Morrissey S., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 360:2002;2018-2025
3. The IFNß Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
4. Paty D, Li D. The UBC MS/MRI Study Group and The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-67.
5. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
6. Jacobs L., Cookfair D., Rudick R., Herndon R., Richert J., Salazar A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:1996;285-294
7. Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
8. European Study Group on interferon β-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon ß-1b in treatment of secondary progressive mutliple sclerosis. Lancet 1998; 352:1491-7.
9. Johnson K., Brooks B., Cohen J., Ford C., Goldstein J., Lisak R., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 45:1995;1268-1276
10. Aimard G., Girard P., Raveau J. Sclérose en plaques et processus d'auto-immunisation. Traitement par les anti-mitotiques. Lyon Médical. 215:1966;345-352
11. Girard P., Aimard G., Pellet H. Thérapeutique immuno- dépressive en neurologie. Presse Méd. 75:1967;967-968
12. Yudkin P., Ellison G., Ghezzi A., Hughes R., McPherson K., Mertin J., et al. Overview of azathioprine treatment in multiple sclerosis. Lancet. 338:1991;1051-1055
13. Palace J., Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet. 350:1997;261
14. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;ii:179-83.
15. Goodkin D., Bailly R., Teetzen M., Hertsgaard D., Beatty W. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology. 41:1991;20-25
16. Hauser S., Dawson D., Lehrich J., Beall M., Kevy S., Propper R., et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Eng. J. Med. 308:1983;173-180
17. Hommes O., Prick J., Lamers K. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg. 78:1975;59-72
18. Gonsette R., Demonty L., Delmotte P. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years. J. Neurol. 214:1977;173-181
19. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;37:441-6.
20. Pedersen-Bjergaard J., Ersböll J., Hansen V., Sorensen B., Christoffersen K., Hou-Jensen K., et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N. Engl. J. Med. 318:1988;1028-1032
21. Moreau T., Thorpe J., Miller D., Moseley I., Hale G., Waldmann H., et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet. 344:1994;298-301
22. Coles A., Wing M., Molyneux P., Paolillo A., Davie C., Hale G., et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46:1999;296-304
23. Patti F., Cataldi M., Nicoletti F., Reggio E., Nicoletti A., Reggio A. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 71:2001;404-407
24. Confavreux C., Saddier P., Grimaud J., Moreau T., Adeleine P., Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology. 46:1996;1607-1612
25. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:2000;707-717
26. Markovic-Plese S., Bielekova B., Kadom N., Leist T.P., Martin R., Frank J.A., et al. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology. 60:2003;1849-1851
27. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B for the Austrian Immunoglobulin in Multiple Sclerosis Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-93.
28. Lhermitte F., Marteau R., Roullet E. Not so benign long-term immunosupression in multiple sclerosis. Lancet. 1:1984;276-277
29. Confavreux C., Vukusic S., Moreau T., Adeleine P. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343:2000;1430-1438
30. Confavreux C., Vukusic S., Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 126:2003;770-782
31. Kurtzke J. On the evaluation of disability in multiple sclerosis. Neurology. 11:1961;686-694
32. Kurtzke J. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452
33. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-504.
34. Cohen J., Cutter G., Fischer J., Goodman A., Heidenreich F., Kooijmans M., et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 59:2002;679-687
35. Rudick R., Fisher E., Lee J., Simon J., Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 53:1999;1698-1704
36. Molyneux P., Kappos L., Polman C., Pozzilli C., Barkhof F., Filippi M., et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive multiple sclerosis. Brain. 123:2000;2256-2263
37. Waubant E., Vukusic S., Gignoux L., Durand-Dubief F., Achiti I., Blanc S., et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology. 61:2003;184-189
38. Chang A., Tourtelotte W., Rudick R., Trapp B. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Eng. J. Med. 346:2002;165-173
39. Pluchino S., Quattrini A., Brambilla E., Gritti A., Salani G., Dina G., et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature. 422:2003;688-694